目的 评价双价肾综合征出血热纯化疫苗(Vero细胞)在6～15岁儿童和>60岁老年人中的免疫原性.方法对知情同意的500名6～15岁(儿童组)、16～60岁(成年人组)和>60岁(老年人组)的健康人群按2∶1∶2的人数比例非随机接种双价肾综合征出血热纯化疫苗(Vero细胞),其中以成年人组作为对照.用ELISA和空斑减少中和试验测定儿童和老年人接种疫苗后的抗体阳转率和几何平均滴度(GMT).结果经ELISA测定,试验组(儿童和老年人)免疫后的抗体阳转率与成年人对照组的差异无统计学意义;老年人组与成年人组的抗体GMT差异无统计学意义,儿童组的GMT水平低于成年人组,差异有统计学意义,但GMT达到有效保护水平.经空斑减少中和试验测定,试验组的抗体阳转率和GMT与对照组的差异均无统计学意义.结论疫苗对≥6岁的所有健康人群接种(禁忌证除外)均具有良好的免疫效果.%Objective To evaluate the immunogenicity of purified bivalent hemorrhagic fever with renal syndrome (HFRS) vaccine (Veto cell) in children (6-15 years) and the elderly (over 60 years). Methods Five hundred healthy people aged 6-15, 16-60, and> 60 were nonrandomly inoculated with tive rate and GMT were determined by ELISA method and plaque reduction neutralization test. Results There were no significant differences of antibody positive rates by ELISA method between the test groups (children and the elderly) and the control. No significant difference of GMT level was found between the elderly group and the control,but the GMT level in children, which was still protective, was significantly lower than that in the control group. There were no significant differences of antibody positive rates and GMT levels by plaque reduction neutralization test between the test groups and the control. Conclusions The purified HFRS vaccine has good immune effect in the healthy people of 6 years and above (with the exception of contraindications).
展开▼
